Jul 17, 2025 | Press Releases
Leaders in clinical, product innovation, and market access will provide guidance for PlaqueIQTM strategy BOSTON and SCCT ANNUAL MEETING, MONTREAL – July 17, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of...
Jul 15, 2025 | Press Releases
New reimbursement recommendations support earlier, non-invasive identification of high-risk cardiovascular patients BOSTON – July 15, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...
Jul 14, 2025 | In the News
Coverage recommended for coronary CTA plaque quantification and analysis to improve clinical diagnosis and management of CAD BOSTON – July 14, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis...
Jul 10, 2025 | Press Releases
Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...
Nov 4, 2024 | In the News
Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers BOSTON – November 4, 2024 – Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare &...